Real-World Assessment of Dupilumab in Chinese Atopic Dermatitis Patients: Efficacy, Safety, and Impact of Comorbidities
Dupilumab effectively improves AD symptoms and comorbidities, with consistent efficacy across comorbid status and good safety profile. Higher baseline disease severity associates with better treatment response.
Authors
- Le Li
- Nan Huang (ORCID: https://orcid.org/0000-0002-1102-7650)
- Dongxia Ma (ORCID: https://orcid.org/0000-0002-7415-3259)
- Rongfei Zhu (ORCID: https://orcid.org/0000-0003-2103-3381)
- Qingxiu Xu (ORCID: https://orcid.org/0009-0000-9950-891X)
- Yaqi Yang (ORCID: https://orcid.org/0000-0001-9460-6860)
- Ping Zhang (ORCID: https://orcid.org/0000-0001-9163-6191)
- Liu Jin (ORCID: https://orcid.org/0009-0000-2964-0480)
- Wenjing Li (ORCID: https://orcid.org/0000-0002-8303-7604)
- Yangxue Fu (ORCID: https://orcid.org/0009-0001-9531-7785)
- Hao Chen (ORCID: https://orcid.org/0000-0001-6959-5450)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-12-01
- DOI
- https://doi.org/10.2147/jaa.s567753
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Tongji University